Nanochon Receives Panamá Regulatory Approval to Initiate First-in-Human Study of Chondrograft™ for Knee Cartilage Defects
核心洞察
Nanochon (搜索) received regulatory approval from Panamá's Ministry of Health to initiate its First-in-Human clinical study of Chondrograft™ (搜索), a novel implant for articular cartilage defects (搜索) of the knee.
The prospective study will evaluate the safety and performance of Chondrograft™ (搜索) in patients aged 22–60 with focal chondral defects (搜索) who have failed conservative treatment.
The trial will be conducted at The Panama Clinic under Principal Investigator Dr. Juan Osorio, with the company also holding Health Canada authorization and actively recruiting patients in Ontario.
Nanochon (搜索), a medical device company developing Chondrograft™ (搜索), a novel patented implant for the treatment of articular cartilage defects (搜索) of the knee, announced on August 14, 2026 that it has received regulatory approval from Panamá's Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects (搜索) of the knee, representing a major milestone in the company's clinical and regulatory development strategy.
Trial Design and Patient Population
The prospective FIH study will enroll patients between the ages of 22 and 60 who have failed conservative treatment and present with one or two femoral condyle and/or trochlear cartilage lesions. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study.
"I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry," Dr. Osorio stated.
Regulatory Strategy and Geographic Expansion
Nanochon (搜索) selected Panamá for its growing reputation as a strategic destination for medical innovation, supported by efficient regulatory pathways, internationally recognized clinical infrastructure, and access to diverse patient populations. In addition to the Panamá approval, the company has received Health Canada authorization to conduct the study in Canada and is actively recruiting patients in Ontario.
"This approval marks a significant milestone for Nanochon (搜索) and validates the momentum behind our clinical development program," said Ben Holmes, Co-Founder and Chief Executive Officer of Nanochon. "Panamá's streamlined regulatory environment and strong clinical ecosystem provide an excellent foundation for advancing innovative orthopedic technologies like Chondrograft™ (搜索) into human studies."
Clinical Significance and Unmet Need
Articular cartilage injuries remain one of the most challenging conditions in orthopedic medicine, often leading to chronic pain, reduced mobility, and progressive joint degeneration. Current treatment approaches can involve lengthy rehabilitation periods and frequently do not restore durable, functional cartilage tissue.
Chondrograft™ (搜索) is designed as a minimally invasive, "burn-no-bridges" solution intended to provide immediate mechanical support and longer-term cartilage regeneration while preserving future treatment options for patients suffering from focal cartilage injuries of the knee. The device was granted Breakthrough Device Designation from the U.S. Food and Drug Administration.
Nanochon (搜索), Inc. is a medical device company developing innovative solutions for cartilage repair in patients who are not yet candidates for joint replacement. The company's lead technology, Chondrograft™ (搜索), is designed to address focal cartilage defects through a minimally invasive regenerative approach.